Vmbook Online ordering

Icons

**Company Information**

**Name:** Repeat-1

**Symbol:** REPEAT-1

**Exchange:** NASDAQ

**Industry:** Biotechnology

**Business Overview**

Repeat-1 is a clinical-stage biotechnology company developing novel gene therapies for the treatment of rare genetic diseases. The company's lead candidate, RP-1, is a gene therapy for the treatment of Retinitis Pigmentosa (RP), a rare genetic disorder that causes progressive vision loss.

**Earnings and Growth**

* **Revenue:** Repeat-1 has not yet generated any revenue from product sales.

* **Earnings per Share (EPS):** Repeat-1 has not yet reported any positive earnings per share.

* **Growth:** The company is in the early stages of development and has not yet achieved significant growth.

**Key Metrics**

* **Market Cap:** $245.6 million (as of March 8, 2023)

* **Trailing Price-to-Earnings (P/E):** N/A

* **Price-to-Book (P/B):** 2.7

* **Debt-to-Equity Ratio:** 0.0

**Recent Developments**

* **Phase 2b/3 Clinical Trial:** Repeat-1 is currently conducting a Phase 2b/3 clinical trial of RP-1 in patients with RP.

* **Collaboration with Roche:** In 2022, Repeat-1 entered into a collaboration with Roche to develop and commercialize RP-1 for the treatment of RP.

* **Public Offering:** In 2022, Repeat-1 raised $110 million through a public offering.

**Risks**

* **Clinical Trial Risk:** The success of Repeat-1's business depends on the successful completion of its clinical trials.

* **Competition:** Repeat-1 faces competition from other companies developing gene therapies for RP.

* **Regulatory Risk:** The company's products must be approved by regulatory agencies before they can be commercialized.

**Analyst Coverage**

Repeat-1 is covered by several analysts, including:

* Leerink Partners

* Piper Sandler

* Oppenheimer & Co.

**Conclusion**

Repeat-1 is a promising biotechnology company with a potential blockbuster product in RP-1. However, the company is still in the early stages of development and faces significant risks. Investors should carefully consider these risks before investing in Repeat-1.